Compare LSTA & SVRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LSTA | SVRN |
|---|---|---|
| Founded | 1980 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9M | 17.0M |
| IPO Year | 2000 | 2021 |
| Metric | LSTA | SVRN |
|---|---|---|
| Price | $1.00 | $34.16 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 78.9K | ★ 151.8K |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.42 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,283,868.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 56.90 | N/A |
| 52 Week Low | $0.96 | $0.16 |
| 52 Week High | $5.07 | $74.74 |
| Indicator | LSTA | SVRN |
|---|---|---|
| Relative Strength Index (RSI) | 34.39 | 50.48 |
| Support Level | $0.99 | $4.53 |
| Resistance Level | $1.28 | $52.00 |
| Average True Range (ATR) | 0.10 | 7.07 |
| MACD | -0.00 | -2.05 |
| Stochastic Oscillator | 11.02 | 40.58 |
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.
Svrn Inc operates in the digital asset and blockchain sector, with a focus on the NEAR Protocol. Its activities include managing a digital asset treasury comprising NEAR, promoting commercial adoption of NEAR-based products, and backing, building, and acquiring ventures that serve its mission.